Screener
Ionis Pharmaceuticals IONS Compensation and benefits
Compensation and benefits at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Amortization of debt issuance costs | 4,150 | 3,288 |
| Non-cash royalty revenue related to sale of royalties | (22,387) | (24,894) |
| Non-cash interest related to sale of future royalties | 34,538 | 37,165 |
| Stock-based compensation expense | 88,870 | 59,408 |
| Loss (gain) on investments, net | (12,401) | 20,471 |
| Non-cash losses related to other assets | 481 | 297 |
| Changes in operating assets and liabilities: | ||
| Contracts receivable | 7,214 | 39,608 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's compensation and benefits?
- Ionis Pharmaceuticals (IONS) reported compensation and benefits of $45.6M in Q2 2026.
- How has Ionis Pharmaceuticals's compensation and benefits changed year-over-year?
- Ionis Pharmaceuticals's compensation and benefits increased by 53.6% year-over-year, from $29.69M to $45.6M.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about Ionis Pharmaceuticals's compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude